Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Antioxidant cocktail may shield seniors from bed rest damage

NCT ID NCT04351113

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study looks at whether antioxidant supplements can prevent muscle loss and blood vessel problems in older adults (ages 65-85) during five days of bed rest. Participants take either a placebo or two antioxidants (MITO-AO and PB-125) while researchers measure changes in blood flow and muscle function. The goal is to understand how inactivity harms the body and find ways to protect it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MITO-AO and PB-125 (dietary supplements)
What this could lead to
If successful, this could point toward a simple supplement strategy to protect older adults from muscle loss and blood vessel problems during hospital stays or bed rest.
What could go wrong
This is an early-stage study with only 82 participants, so results may not apply to everyone. The supplements may not work as hoped, and the study focuses on short-term bed rest, not long-term inactivity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

82 people

The number who actually took part.

Started

Sep 2019

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 65-85 yrs * Ability to sign informed consent * Montreal cognitive assessment (MOCA) exam score greater-than or equal to 26 4. Free-living, prior to admission Exclusion Criteria: * Cardiac abnormalities considered exclusionary by the study physician (e.g., congestive heart failure (CHF), coronary artery disease (CAD), right-to-left shunt) * Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes) * Glomerular filtration rate (GFR) less-than 30 mL/min/1.73m2 or evidence of kidney disease or failure * Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia greater-than 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries) * Risk of deep vein thrombosis (DVT) including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb greater-than 18 g/dL) or thrombocytosis (platelets greater-than 400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombin III * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Elevated systolic pressure greater-than 150 or a diastolic blood pressure greater-than 100 (treated or untreated) * Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Currently on a weight-loss diet or body mass index greater-than 35 kg/m2 (a BMI of 35 kg/m2, which includes individuals that fall into to the Class I obesity category, has been selected to improve inclusion and generalizability to a greater percentage of the general population). * Inability to abstain from smoking for duration of study * A history of greater-than 20 pack per year smoking * HIV or hepatitis B or C\* * Recent anabolic or corticosteroids use (within 3 months) * Subjects with hemoglobin or hematocrit lower than accepted lab values * Agitation/aggression disorder (by psychiatric history and exam) * History of stroke with motor disability * A recent history (less-than 12 months) of GI bleed * Depression \[greater-than 5 on the 15 items Geriatric Depression Scale (GDS)\] * Alcohol abuse (greater-than 2 drinks per day) or drug abuse (inappropriate use of prescription medications or use of any illicit/illegal drugs for recreational use) * Exercise training (greater-than 1 session of moderate to high intensity aerobic or resistance exercise/week) * Liver disease (aspartate aminotransferase/alanine aminotransferase 2 times above the normal limit, hyperbilirubinemia) * Respiratory disease (acute upper respiratory infection, history of chronic lung disease with resting oxygen saturation less-than 97% on room air) * Currently taking a mitochondrial targeted antioxidant or similarly acting nutraceutical * Unwilling to cease dietary supplements 4 weeks prior to initiation of bed rest * Participated in similar bed rest study during last 12 months * Any other condition or event considered exclusionary by the PI and faculty physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • VA Medical Center

    Salt Lake City, Utah, 84148, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.